H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Bausch + Lomb Corporation (BLCO – Research Report) today and set a price target of $23.00. Yi Chen has given his Buy rating due to a ...

Bausch Health Companies ( (BHC)) has realeased its Q3 earnings. Here is a breakdown of the information Bausch Health Companies presented to its investors. Bausch Health Companies Inc., a ...

“I’m optimistic,” Bausch + Lomb CEO Brent Saunders told STAT. Zach Weinberg, CEO of Curie.Bio, said that while Trump’s policies on health care have been known to shift, “R.F.K. is scary ...

Bausch + Lomb shares surged Monday following reports Blackstone and TPG are considering teaming up to buy the eyecare company. A bid from Blackstone and TPG could reportedly value the company ...

Bausch Health turned down recent debt-restructuring proposals from bondholders as it explores a sale of its Bausch + Lomb vision care subsidiary that could bring in billions of dollars to pay ...

Bausch & Lomb (NYSE:BLCO) jumped 7.5% on a report that private equity firms TPG (TPG) and Blackstone (BX) are working on a joint bid for the eyecare company. Several other PE shops that have been ...

Monday was an eventful day for Bausch + Lomb (NYSE: BLCO). The eye care specialist's major piece of internal news was that it earned its latest Food and Drug Administration (FDA) approval.

It isn't known whether Bausch + Lomb and/or Goldman is in contact with either Blackstone or TPG. According to the FT, several private equity funds mulling offers have dropped out of the race.

Private equity players TPG and Blackstone are planning a joint bid for Canadian contact lens supplier Bausch + Lomb, Financial Times reported on October 14 citing people familiar with the matter.